Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study
Yıl: 2023 Cilt: 24 Sayı: 2 Sayfa Aralığı: 116 - 119 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2023.38387 İndeks Tarihi: 06-06-2023
Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study
Öz: Introduction: Chronic hepatitis C virus (HCV) infection is one of the important causes of liver cancer and cirrhosis all over the worldwide. Methods: The data of the patients diagnosed with chronic hepatitis C infection who applied to the Adult Infectious Diseases and Clinical Microbiology Outpatient Clinic of Erzincan Binali Yildirim University, Mengücek Gazi Training and Research Hospital were retrospectively analyzed. Accordingly, 51 patients treated with direct-acting oral antiviral drugs (DAAs) between January 2016 and May 2021 were included in the study. Patients whose treatment is still ongoing, whose treatment was completed but did not come to the 12th week after treatment, or whose control time has not yet come, were excluded from the study. Results: It was observed that 58.8% of the cases participating in the study were male, 80.4% were infected with genotype 1b, and 74.5% were treatment-naive. When the treatment regimens used in the cases were examined, glecaprevir/pibrentasvir in 7.8%, sofosbuvir (SOF)/ledipasvir (LED), SOF/LED/ribavirin, and SOF/ribavirin in 15.7%, ombitasvir (OBV)/paritaprevir (P)/ritonavir (R)/dasabuvir and OBV/P/R/ribavirin in 76.5% (n=39) appears to be used. A statistically significant difference was found between the alanine aminotransferase, aspartate aminotransferase measurements, and platelet counts of the subjects participating in the study at the beginning, at the 4th week, at the end of the treatment, and at the 12th week (p=0.001). In these cases, a sustained virological response was achieved in 100%. In the follow-up of the cases, no serious side effects that required drug discontinuation were observed. Conclusion: Our study showed that the treatment success of DAAs is 100% and their side-effect profiles are good.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. World Health Organization (WHO) (2017) Global hepatitis report. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/hand le/10665/255016/9789241565455-eng.pdf?sequence=1
- 2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161-76.
- 3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-57.
- 4. Kırdar S, Yaşa MH, Aydın N, Korkmazgil Gültekin B, Öztürk ŞB, Kurt Ömürlü İ. The Distribution of Hepatitis C Virus Genotypes in Patients with Chronic Hepatitis C Infection. Meandros Medical Journal 2015; 16: 108-13.
- 5. Altuğlu I, Sertöz R, Aksoy A, Gürsel D, Tüzüner U, Günşar F. Possible transmission risks and genotype distribution of hepatitis C virus infection in Western Turkey. Turk J Gastroenterol 2013; 24: 349-55.
- 6. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-6.
- 7. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 325-36.
- 8. Aygen B, Demirtürk N, Yıldız O, Çelik İ, Güzel DK, Ersöz G, et al. Ombitasvir/ Paritaprevir/ Ritonavir + Ribavirin Combination Therapy in Hepatitis C Virus Infected Patients with Genotype 4 in Real-life Practice: A Multicentre Experience. Infect Dis Clin Microbiol 2019; 1: 97-107.
- 9. Aygen B, Demirtürk N, Yıldız O, Çelen MK, Çelik İ, Barut Ş, et al. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turk J Gastroenterol 2020; 31: 305-17.
- 10. Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, et al. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016; 33: 18-26.
- 11. Dai CY, Chuang WL, Yu ML. EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues. J Hepatol 2021; 74: 473-4.
- 12. Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, et al. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. J Clin Med 2021; 10: 5236.
- 13. Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, et al. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021; 120: 1259-68.
- 14. Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, et al. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol 2021; 36: 2884-92.
- 15. Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct- acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. J Viral Hepat 2021; 28: 739-54.
- 16. Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, et al. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. J Viral Hepat 2021; 28: 168-76.
- 17. Öztürk-Çerik H, Esen Ş, Altıntaş-Öner B, Çelik M, Özdemir T, Tanyel E. Evaluation of the Effectiveness of Direct-Acting Antiviral Agents in Patients With Hepatitis C. Klimik Dergisi 2020; 33: 297-306.
- 18. Akar M, Solakoğlu T. Real life data of second generation direct acting oral antivirals in the treatment of chronic hepatitis C:A single center and heterogeneous patient group. The Turkish Journal of Academic Gastroenterology 2020; 19: 123-8.
APA | Binay U, karakeçili f, Barkay O, Gül Ö (2023). Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. , 116 - 119. 10.4274/imj.galenos.2023.38387 |
Chicago | Binay Umut Devrim,karakeçili faruk,Barkay Orçun,Gül Özlem Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. (2023): 116 - 119. 10.4274/imj.galenos.2023.38387 |
MLA | Binay Umut Devrim,karakeçili faruk,Barkay Orçun,Gül Özlem Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. , 2023, ss.116 - 119. 10.4274/imj.galenos.2023.38387 |
AMA | Binay U,karakeçili f,Barkay O,Gül Ö Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. . 2023; 116 - 119. 10.4274/imj.galenos.2023.38387 |
Vancouver | Binay U,karakeçili f,Barkay O,Gül Ö Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. . 2023; 116 - 119. 10.4274/imj.galenos.2023.38387 |
IEEE | Binay U,karakeçili f,Barkay O,Gül Ö "Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study." , ss.116 - 119, 2023. 10.4274/imj.galenos.2023.38387 |
ISNAD | Binay, Umut Devrim vd. "Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study". (2023), 116-119. https://doi.org/10.4274/imj.galenos.2023.38387 |
APA | Binay U, karakeçili f, Barkay O, Gül Ö (2023). Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. İstanbul Medical Journal, 24(2), 116 - 119. 10.4274/imj.galenos.2023.38387 |
Chicago | Binay Umut Devrim,karakeçili faruk,Barkay Orçun,Gül Özlem Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. İstanbul Medical Journal 24, no.2 (2023): 116 - 119. 10.4274/imj.galenos.2023.38387 |
MLA | Binay Umut Devrim,karakeçili faruk,Barkay Orçun,Gül Özlem Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. İstanbul Medical Journal, vol.24, no.2, 2023, ss.116 - 119. 10.4274/imj.galenos.2023.38387 |
AMA | Binay U,karakeçili f,Barkay O,Gül Ö Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. İstanbul Medical Journal. 2023; 24(2): 116 - 119. 10.4274/imj.galenos.2023.38387 |
Vancouver | Binay U,karakeçili f,Barkay O,Gül Ö Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study. İstanbul Medical Journal. 2023; 24(2): 116 - 119. 10.4274/imj.galenos.2023.38387 |
IEEE | Binay U,karakeçili f,Barkay O,Gül Ö "Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study." İstanbul Medical Journal, 24, ss.116 - 119, 2023. 10.4274/imj.galenos.2023.38387 |
ISNAD | Binay, Umut Devrim vd. "Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study". İstanbul Medical Journal 24/2 (2023), 116-119. https://doi.org/10.4274/imj.galenos.2023.38387 |